Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets

Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets

Abstract The adenovirus (Ad)26 serotype–based vector vaccine Ad26.COV2.S has been used in millions of subjects for the prevention of COVID-19, but potentially elicits persistent anti-vector immunity. We investigated if vaccine-elicited immunity to Ad26 vector–based vaccines significantly influences...

Full description

Bibliographic Details
Main Authors: Selina Khan, Nadine C. Salisch, Ana Izquierdo Gil, Satish Boedhoe, Karin Feddes-de Boer, Jan Serroyen, Hanneke Schuitemaker, Roland C. Zahn
Format: Article
Language:English
Published: Nature Portfolio 2022-11-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-022-00567-w

Similar Items

Similar Items